Meltem Selam - Academia.edu (original) (raw)

Papers by Meltem Selam

Case Reports, Feb 8, 2013

International Journal of Clinical Oncology, May 23, 2021

dose density was significantly associated with progression-free survival (P = 0.003). Notably, ne... more dose density was significantly associated with progression-free survival (P = 0.003). Notably, neither the Memorial Sloan-Kettering Cancer Center criteria nor the Medical Research Council criteria for relapsed GCT were able to identify a poor-prognostic group for GAMEC. The authors conclude that GAMEC is an effective treatment for patients with untreated or relapsed GCT, although it results in substantial toxic effects. Original article Shamash J et al. (2007) GAMEC-a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours.

Journal of Gastrointestinal Cancer, May 14, 2015

Leptomeningeal carcinomatosis (carcinomatous meningitis) (LC) is a rare complication of solid can... more Leptomeningeal carcinomatosis (carcinomatous meningitis) (LC) is a rare complication of solid cancers or hematologic malignancies. LC secondary to gastrointestinal solid tumors is rare [1]. LC frequency due to metastatic esophageal adenocarcinoma is 0.25 % [1]. Case Presentation A 46-year-old male patient presented with a 1-month history of solid food dysphagia and accompanying weight loss. His family history was negative. His physical examination was normal. A distal 1/3 esophageal mass was found on endoscopy and PET CT. He received 3 cycles of chemotherapy consisting of docetaxel, cisplatin, and capecitabine prior to his operation. He complained of tinnitus during this period, which was attributed to a side effect of chemotherapy. He was operated 1 month after the chemotherapy. Pathology revealed a moderately differentiated lymphadenopathypositive adenocarcinoma (T3 N3 M0). His chemotherapy was initiated post-operatively; he received 2 cycles of docetaxel, carboplatin, and capecitabine.

European urology focus, Sep 1, 2020

Background: Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previ... more Background: Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies in patients with locally advanced or metastatic platinumresistant urothelial carcinoma. Objective: To compare the real-life experience and data of clinical trials on ATZ treatment in metastatic urothelial carcinoma. Design, setting, and participants: Patients with urothelial cancer treated with ATZ after progression on first-line chemotherapy from an expanded access program were retrospectively studied. Data of patients were obtained from their files and hospital records. Safety was evaluated for patients treated with at least one cycle of ATZ. Outcome measurements and statistical analysis: The primary endpoint was objective response rate (ORR). The secondary endpoints are overall survival (OS), progression-free

Cancer Chemother Pharmacol, 2008

Journal of Gastrointestinal Cancer, 2015

Leptomeningeal carcinomatosis (carcinomatous meningitis) (LC) is a rare complication of solid can... more Leptomeningeal carcinomatosis (carcinomatous meningitis) (LC) is a rare complication of solid cancers or hematologic malignancies. LC secondary to gastrointestinal solid tumors is rare [1]. LC frequency due to metastatic esophageal adenocarcinoma is 0.25 % [1]. Case Presentation A 46-year-old male patient presented with a 1-month history of solid food dysphagia and accompanying weight loss. His family history was negative. His physical examination was normal. A distal 1/3 esophageal mass was found on endoscopy and PET CT. He received 3 cycles of chemotherapy consisting of docetaxel, cisplatin, and capecitabine prior to his operation. He complained of tinnitus during this period, which was attributed to a side effect of chemotherapy. He was operated 1 month after the chemotherapy. Pathology revealed a moderately differentiated lymphadenopathypositive adenocarcinoma (T3 N3 M0). His chemotherapy was initiated post-operatively; he received 2 cycles of docetaxel, carboplatin, and capecitabine.

Cancer Chemotherapy and Pharmacology, 2007

Angiogenesis is regulated by a balance of both angiogenic inducers and inhibitors. This study was... more Angiogenesis is regulated by a balance of both angiogenic inducers and inhibitors. This study was designed to evaluate the effect of both maximum-tolerated doses (MTD) and low-dose metronomic chemotherapy (LDM) on serum vascular endothelial growth factor (VEGF), thrombospondin-1 (TSP1) and VEGFR1 concentrations in patients with advanced nonsmall cell lung cancer. Forty consecutive patients with advanced stage nonsmall cell lung cancer were included in this prospective study. Twenty patients received MTD chemotherapy including 75 mg/m2 of cisplatin and 75 mg/m2 of docetaxel on day 1. The LDM treatment consisted of cisplatin 25 mg/m2 and docetaxel 25 mg/m2 were given to other 20 patients on weeks 1, 2 and 3. Serum levels were prospectively measured in serum by ELISA at four times; before chemotherapy and at 1, 2 and 3 weeks following initiation of chemotherapy. The major finding in this study that MTD chemotherapy but not LDM chemotherapy resulted in significant changes in VEGFR1 and TSP1 serum levels. Due to the effect of LDM chemotherapy, we showed no statistically significant change in patients for all serum VEGF, TSP1 and VEGFR1 levels. Similarly, serum VEGF levels did not also change under MTD chemotherapy. The MTD chemotherapy induced significant and long-lasting increase of TSP1 levels and decrease of VEGFR1 levels that persisted for at least 3 weeks after the chemotherapy initiation. No significant correlations were found between serum VEGF and TSP1 levels in cancer patients treated with both LDM and MTD chemotherapy. The circulating angiogenic balance (TSP1/VEGF) is decreased in cancer patients (P=0.039). The continuous/metronomic chemotherapy may not achieve a more pronounced antiangiogenic effect than MTD-scheduling chemotherapy. Future studies involving a larger number of patients are needed to confirm the present findings.

Gynecologic Oncology, 2008

To evaluate the clinicopathological prognostic factors and outcome of chemotherapy in ovarian car... more To evaluate the clinicopathological prognostic factors and outcome of chemotherapy in ovarian carcinosarcomas. We reviewed the records of 26 patients treated from 1990 to 2006 at the Oncology Institute of Istanbul University. Clinical data including demographics, stage, surgery, chemotherapy, and survival were collected from patients' charts. All patients underwent initial debulking surgery. Optimal debulking was achieved in 21 (81%) patients. The most striking clinicopathological finding was the high incidence of hemorrhagic ascites (n: 6) which was observed in 60% of the patients with ascites (n: 10). The overall median survival of the patients was 26 months. Residual disease was associated with a decreased overall survival, P=0.04. Median survival (50 months vs 9.7 months, P=0.042) of the patients with early stage disease were longer than the patients with advanced stage. Twenty-two patients received platinum-based combination chemotherapy. There was a trend for increased median survival in the patients who were treated with carboplatin/paclitaxel combination (P=0.066). Although the numbers were insufficient for statistical evaluation, the patients treated with ifosfamide combinations had improved survival (36 months vs 26 months). However, when the patients treated with ifosfamide and carboplatin/paclitaxel combinations were combined, survival was statistically improved compared to the other regimens (36 months vs 9.7 months, P=0.04). Chemotherapy regimens containing doxorubicin or cyclophosphamide were not encouraging. Stage (P=0.02) and adjuvant platinum-based chemotherapy containing either paclitaxel or ifosfamide (P=0.024) remained predictive of outcome in the multivariate analysis. Hemorrhagic ascites can be used in the initial differential diagnosis of ovarian carcinosarcomas. Stage, optimal debulking and type of adjuvant therapy were statistically significant prognostic predictors of ovarian carcinosarcomas. We advise that patients with ovarian carcinosarcomas should be treated by optimal cytoreduction followed by adjuvant platinum/taxan or platinum/ifosfamide combinations.

International Journal of Clinical Oncology, 2021

Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies ... more Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies of patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of Atezolizumab was modest. In the current study, we evaluated the pretreatment prognostic factors for overall survival in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy in the Expanded-Access Program of Atezolizumab. In this study, we present a retrospective analysis of 113 patients with urothelial cancer treated with ATZ after progression on first-line chemotherapy. Data of the patients was obtained from patient files and hospital records. Eligible patients included metastatic urothelial carcinoma patients treated with at least one course of ATZ. Univariate analysis was used to identify clinical and laboratory factors that significantly impact OS. Variables were retained for multivariate analysis if they had a statistical relationship with OS ...

Gynecologic Oncology, 2008

Objective. To evaluate the clinicopathological prognostic factors and outcome of chemotherapy in ... more Objective. To evaluate the clinicopathological prognostic factors and outcome of chemotherapy in ovarian carcinosarcomas. Methods. We reviewed the records of 26 patients treated from 1990 to 2006 at the Oncology Institute of Istanbul University. Clinical data including demographics, stage, surgery, chemotherapy, and survival were collected from patients' charts.

Case Reports, Feb 8, 2013

International Journal of Clinical Oncology, May 23, 2021

dose density was significantly associated with progression-free survival (P = 0.003). Notably, ne... more dose density was significantly associated with progression-free survival (P = 0.003). Notably, neither the Memorial Sloan-Kettering Cancer Center criteria nor the Medical Research Council criteria for relapsed GCT were able to identify a poor-prognostic group for GAMEC. The authors conclude that GAMEC is an effective treatment for patients with untreated or relapsed GCT, although it results in substantial toxic effects. Original article Shamash J et al. (2007) GAMEC-a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours.

Journal of Gastrointestinal Cancer, May 14, 2015

Leptomeningeal carcinomatosis (carcinomatous meningitis) (LC) is a rare complication of solid can... more Leptomeningeal carcinomatosis (carcinomatous meningitis) (LC) is a rare complication of solid cancers or hematologic malignancies. LC secondary to gastrointestinal solid tumors is rare [1]. LC frequency due to metastatic esophageal adenocarcinoma is 0.25 % [1]. Case Presentation A 46-year-old male patient presented with a 1-month history of solid food dysphagia and accompanying weight loss. His family history was negative. His physical examination was normal. A distal 1/3 esophageal mass was found on endoscopy and PET CT. He received 3 cycles of chemotherapy consisting of docetaxel, cisplatin, and capecitabine prior to his operation. He complained of tinnitus during this period, which was attributed to a side effect of chemotherapy. He was operated 1 month after the chemotherapy. Pathology revealed a moderately differentiated lymphadenopathypositive adenocarcinoma (T3 N3 M0). His chemotherapy was initiated post-operatively; he received 2 cycles of docetaxel, carboplatin, and capecitabine.

European urology focus, Sep 1, 2020

Background: Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previ... more Background: Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies in patients with locally advanced or metastatic platinumresistant urothelial carcinoma. Objective: To compare the real-life experience and data of clinical trials on ATZ treatment in metastatic urothelial carcinoma. Design, setting, and participants: Patients with urothelial cancer treated with ATZ after progression on first-line chemotherapy from an expanded access program were retrospectively studied. Data of patients were obtained from their files and hospital records. Safety was evaluated for patients treated with at least one cycle of ATZ. Outcome measurements and statistical analysis: The primary endpoint was objective response rate (ORR). The secondary endpoints are overall survival (OS), progression-free

Cancer Chemother Pharmacol, 2008

Journal of Gastrointestinal Cancer, 2015

Leptomeningeal carcinomatosis (carcinomatous meningitis) (LC) is a rare complication of solid can... more Leptomeningeal carcinomatosis (carcinomatous meningitis) (LC) is a rare complication of solid cancers or hematologic malignancies. LC secondary to gastrointestinal solid tumors is rare [1]. LC frequency due to metastatic esophageal adenocarcinoma is 0.25 % [1]. Case Presentation A 46-year-old male patient presented with a 1-month history of solid food dysphagia and accompanying weight loss. His family history was negative. His physical examination was normal. A distal 1/3 esophageal mass was found on endoscopy and PET CT. He received 3 cycles of chemotherapy consisting of docetaxel, cisplatin, and capecitabine prior to his operation. He complained of tinnitus during this period, which was attributed to a side effect of chemotherapy. He was operated 1 month after the chemotherapy. Pathology revealed a moderately differentiated lymphadenopathypositive adenocarcinoma (T3 N3 M0). His chemotherapy was initiated post-operatively; he received 2 cycles of docetaxel, carboplatin, and capecitabine.

Cancer Chemotherapy and Pharmacology, 2007

Angiogenesis is regulated by a balance of both angiogenic inducers and inhibitors. This study was... more Angiogenesis is regulated by a balance of both angiogenic inducers and inhibitors. This study was designed to evaluate the effect of both maximum-tolerated doses (MTD) and low-dose metronomic chemotherapy (LDM) on serum vascular endothelial growth factor (VEGF), thrombospondin-1 (TSP1) and VEGFR1 concentrations in patients with advanced nonsmall cell lung cancer. Forty consecutive patients with advanced stage nonsmall cell lung cancer were included in this prospective study. Twenty patients received MTD chemotherapy including 75 mg/m2 of cisplatin and 75 mg/m2 of docetaxel on day 1. The LDM treatment consisted of cisplatin 25 mg/m2 and docetaxel 25 mg/m2 were given to other 20 patients on weeks 1, 2 and 3. Serum levels were prospectively measured in serum by ELISA at four times; before chemotherapy and at 1, 2 and 3 weeks following initiation of chemotherapy. The major finding in this study that MTD chemotherapy but not LDM chemotherapy resulted in significant changes in VEGFR1 and TSP1 serum levels. Due to the effect of LDM chemotherapy, we showed no statistically significant change in patients for all serum VEGF, TSP1 and VEGFR1 levels. Similarly, serum VEGF levels did not also change under MTD chemotherapy. The MTD chemotherapy induced significant and long-lasting increase of TSP1 levels and decrease of VEGFR1 levels that persisted for at least 3 weeks after the chemotherapy initiation. No significant correlations were found between serum VEGF and TSP1 levels in cancer patients treated with both LDM and MTD chemotherapy. The circulating angiogenic balance (TSP1/VEGF) is decreased in cancer patients (P=0.039). The continuous/metronomic chemotherapy may not achieve a more pronounced antiangiogenic effect than MTD-scheduling chemotherapy. Future studies involving a larger number of patients are needed to confirm the present findings.

Gynecologic Oncology, 2008

To evaluate the clinicopathological prognostic factors and outcome of chemotherapy in ovarian car... more To evaluate the clinicopathological prognostic factors and outcome of chemotherapy in ovarian carcinosarcomas. We reviewed the records of 26 patients treated from 1990 to 2006 at the Oncology Institute of Istanbul University. Clinical data including demographics, stage, surgery, chemotherapy, and survival were collected from patients' charts. All patients underwent initial debulking surgery. Optimal debulking was achieved in 21 (81%) patients. The most striking clinicopathological finding was the high incidence of hemorrhagic ascites (n: 6) which was observed in 60% of the patients with ascites (n: 10). The overall median survival of the patients was 26 months. Residual disease was associated with a decreased overall survival, P=0.04. Median survival (50 months vs 9.7 months, P=0.042) of the patients with early stage disease were longer than the patients with advanced stage. Twenty-two patients received platinum-based combination chemotherapy. There was a trend for increased median survival in the patients who were treated with carboplatin/paclitaxel combination (P=0.066). Although the numbers were insufficient for statistical evaluation, the patients treated with ifosfamide combinations had improved survival (36 months vs 26 months). However, when the patients treated with ifosfamide and carboplatin/paclitaxel combinations were combined, survival was statistically improved compared to the other regimens (36 months vs 9.7 months, P=0.04). Chemotherapy regimens containing doxorubicin or cyclophosphamide were not encouraging. Stage (P=0.02) and adjuvant platinum-based chemotherapy containing either paclitaxel or ifosfamide (P=0.024) remained predictive of outcome in the multivariate analysis. Hemorrhagic ascites can be used in the initial differential diagnosis of ovarian carcinosarcomas. Stage, optimal debulking and type of adjuvant therapy were statistically significant prognostic predictors of ovarian carcinosarcomas. We advise that patients with ovarian carcinosarcomas should be treated by optimal cytoreduction followed by adjuvant platinum/taxan or platinum/ifosfamide combinations.

International Journal of Clinical Oncology, 2021

Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies ... more Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies of patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of Atezolizumab was modest. In the current study, we evaluated the pretreatment prognostic factors for overall survival in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy in the Expanded-Access Program of Atezolizumab. In this study, we present a retrospective analysis of 113 patients with urothelial cancer treated with ATZ after progression on first-line chemotherapy. Data of the patients was obtained from patient files and hospital records. Eligible patients included metastatic urothelial carcinoma patients treated with at least one course of ATZ. Univariate analysis was used to identify clinical and laboratory factors that significantly impact OS. Variables were retained for multivariate analysis if they had a statistical relationship with OS ...

Gynecologic Oncology, 2008

Objective. To evaluate the clinicopathological prognostic factors and outcome of chemotherapy in ... more Objective. To evaluate the clinicopathological prognostic factors and outcome of chemotherapy in ovarian carcinosarcomas. Methods. We reviewed the records of 26 patients treated from 1990 to 2006 at the Oncology Institute of Istanbul University. Clinical data including demographics, stage, surgery, chemotherapy, and survival were collected from patients' charts.